This is the authors' abstract. We don't add key points for this paper.
Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs. Because of the low number of observed deaths, survival analysis was not confirmatory.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Rinke et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: